At 7.1% CAGR, Europe Hyperpigmentation Disorder Treatment Market is Projected to be Worth US$ 1,911.95 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Europe hyperpigmentation disorder treatment market was valued at US$ 1,100.99 million in 2022 and is projected to reach US$ 1,911.95 million by 2030, registering a CAGR of 7.1% from 2022 to 2030. Rise in prevalence of melasma and strategic initiatives by market players are among the critical factors attributed to drive the Europe hyperpigmentation disorder treatment market growth.

Major hyperpigmentation disorder treatment market players focus on research and development activities to develop and launch innovative and efficient products. They are also making efforts to win regulatory approvals for their products. Some of the recent product developments and launches, which are likely to create ample growth opportunities for market players, are mentioned below.

• In October 2022, Galderma introduced Skincare A-LUMINATE BRIGHTENING SERUM, a breakthrough product in the skincare industry. This innovative addition to the ALASTIN Skincare range is specifically formulated to lower the appearance of surface hyperpigmentation without the use of harsh or irritating ingredients.
  
  
• In February 2022, Alchemee introduced the new Restorative Elements brand to help in the correction of the appearance of various types of skin discoloration and hyperpigmentation symptoms, including age spots, sunspots, uneven skin tone, and post-inflammatory hyperpigmentation (PIH). The Restorative Elements is a dermatologist-developed, clinically-proven routine formulated to safely and gently help fade the visible signs of skin hyperpigmentation.
  
  
• In May 2022, Scientis launched the Cyspera Intensive System, a three-product system formulated to improve hyperpigmentation.

On the contrary, the high cost of treatments hampers the growth of the Europe hyperpigmentation disorder treatment market.

Based on treatment type, the Europe hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held 42.7% market share in 2022, amassing US$ 469.64 million. It is projected to garner US$ 845.36 million by 2030 to register 7.6% CAGR during 2022-2030.

Based on condition, the Europe hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held 47.0% market share in 2022, amassing US$ 517.89 million. It is projected to garner US$ 923.22 million by 2030 to register 7.5% CAGR during 2022-2030.

Based on end user, the Europe hyperpigmentation disorder treatment market is segmented into hospitals, dermatology centers, and others. The hospitals segment held 48.4% market share in 2022, amassing US$ 532.89 million. It is projected to garner US$ 919.22 million by 2030 to register 7.1% CAGR during 2022-2030.

Based on country, the Europe hyperpigmentation disorder treatment market is categorized into Germany, UK, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany captured 25.8% share of Europe hyperpigmentation disorder treatment market in 2022. It was assessed at US$ 283.63 million in 2022 and is likely to hit US$ 499.29 million by 2030, registering a CAGR of 7.3% during 2022-2030.

Key players operating in the Europe hyperpigmentation disorder treatment market are AbbVie Inc, Bayer AG, EpiPharm AG, Galderma SA, L'OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Pierre Fabre SA, among others.

• In September 2023, Galderma launched a new product, C-RADICAL Defense Antioxidant Serum, a new addition to the ALASTIN Skincare product - This serum is formulated with Vitamin C (Sodium Ascorbate) and 14 essential antioxidants that offers a new option in antioxidant serums to protect against environmental stressors, fight free radicals, UV damage, blue light, and pollution while supporting the skin's ability to maintain elastin and can help skin look smoother, more radiant, and healthier.
  
  
• In January 2022, Obagi introduced Skintrinsiq. The skincare device employs Obagi InfuseIQ Technology to raise the topmost layers of the skin, removing impurities and promoting the absorption of Obagi products. Skintrinsiq treatments can be customized to suit all skin types and skin care objectives, ranging from treating fine lines and wrinkles to brightening the skin for a more uniform complexion.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com